• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    The invention relates to a combination preparation for improving the sperm quantity and quality comprising at least one antioxidant, wherein citruliin and / or omega-3 fatty acids is / are contained and citruliin for the treatment of oligozoospermia, asthenozoospermia and / or teratozoospermia.
    公开号:AT511776A1
    申请号:T1093/2011
    申请日:2011-07-26
    公开日:2013-02-15
    发明作者:Birgit Dr Wogatzky；Johannes Dr Wogatzky
    申请人:Gonadosan Gmbh；
    IPC主号:
    专利说明:

    -1 - 15:13:19 26-07-2011 5 '27 25
    The invention relates to a combination preparation for improving the sperm quantity and quality comprising at least one antioxidant or at least one of the active ingredients C vitamins, E vitamins, zinc, selenium, acetylcysteine, L-camitine, glutathione, lycopene, ubiquinone-10 component thereof Use as well as CHrullin to improve sperm quality.
    More and more couples are making their way to the desired child difficult In industrialized countries like Germany and the USA, one in ten couples is unintentionally childless today and the trend is rising. Limited fertility can have many causes. The increasing age of couples wishing to have children may play a role as well as environmental pollution, reduced sperm quality, impaired ova, unhealthy lifestyles and others. So-called "lifestyle factors" are also a decisive factor. One of the prerequisites for fertility in men and women is adequate supply of the body with certain micronutrients, energy substrates and vitamins. An adequate supply of vitamins and certain nutrients is unfortunately increasingly difficult in our time. With increased stress in everyday life with stress, low food quality and unhealthy diet, the human organism is often inadequately supplied. As a result, the body is under constant load and this is especially true where the cells are most sensitive - in the egg and sperm cells. The male sperm become sluggish, oocytes "miss" their ovulation and thus fertility can suffer from malnutrition. It has already been proven in several studies, how much the right nutrition contributes to the fulfillment of the desire to have children. M2011 / 15300 O / J i Λ "7 (ΟΛ1 i 1 C 1 K Mr R *; ni P.005 / 027 25 15:13:56 26-07-2011 6/27 · * * * · · · · ···· * t · «· · · · * • · · * * I ···« · · · · · · · · · · » While the woman is already born with the ova, the sperm are mimicked in the man for a lifetime.On every second unintentionally childless couple of the man is causally involved and in every third case, the cause is even alone with the man In recent decades, the quality of male fertility has been steadily decreasing, one of the most common causes of male immobility is limited sperm quality in the sense of oligozoospermia (too few spermatozoa), asthenozoospermia (too poor motile spermatozoa) or teratozoospermia (too many deformed spermatozoa) It is rare to find all three limitations even in the same patient (OAT syndrome) In addition, the integrity of the DNA transported in the sperm plays an important role in fulfilling the desire for children. A major cause of DNA damage in the sperm is oxidative stress. In the last decade, oxidative stress has become the focus of interest for infertility (Agarwal, 2004). Oxidative stress is defined as damage to cells, tissues or even organs by increased amounts of so-called reactive oxygen species (ROS) (Moller et al, 1996, Sharma and Agarwal, 1996, Saleh et al, 2003). If the amount of reactive oxygen species exceeds the capacity of the body's own antioxidant defense mechanisms, the oxidative stress (OS) mentioned above results. 30-80% of all infertile men have an increased amount of ROS in the semimalpiasma (Agarwal, 2004). In 2009 Varghese et al. In addition, a strong correlation between asthenospermia and reduced antioxidants in seminal fluid can be demonstrated. In particular, in men who produce excessive amounts of reactive oxygen species, normal sperm damage occurs (Aitken et al., 1998, Alvarez et al., 2002, Saleh et al., 2002, Agarwal et al., 2003). Spermatozoa are particularly susceptible to attack by ROS because they lack their own cytoplasmic defense and repair mechanisms (Donnelly et al, 1999, Saleh and Agarwal, 2002). In addition, they have a plasma membrane with a particularly large number of polyunsaturated fatty acids. These are good targets for ROS. (Agarwal et al, 1994, Kobayashi et al, 2001, Zalata et al, 2004). Antioxidants ingested with food N2011 / 15300 M r nc ίΐΛΐ i ic.ic □ cm p nn N / n 7 -3- 4 · · * 15:14:42 26-07-2011 7/27 25 den They are an important part of the human antioxidant defense system, especially in the field of spermiogenesis. Fruits and vegetables are a major source of the various antioxidants, but under today's increasing stress and resulting increased oxidative stress, even with balanced nutrition hardly are still supplied to the required extent. To make matters worse, especially men often do not eat very consciously and healthily. According to a survey of male reproductive health patients, the majority of men believe they are very well fed, even though they say they did not consume more than one to a maximum of two servings of fruit and vegetables a day. Hardly a man reaches the 5 portions of fruit and vegetables recommended by the health authorities of many states (Wogatzky et al, the day before at the 4th International Congress of the Jordanian Society for Fertility and Genetics, 20-22 April 2011). In a Spanish study in 2009, it was shown that men who consumed few antioxidants with food showed on average poorer semen quality (Mendiola et al, 2009).
    For example, the preparation Fertilov'if®M of the Applicant is known. Fertilovit® M contains a combination of vitamins and other nutrients that help the sperm to mature and protect against oxidative stress around the clock with antioxidants in sustained release form. Fertilovit® M for men improves sperm quality through its specific composition of endogenous substances.
    The object of the present invention is therefore to provide an active substance or a combination preparation which further improves the sperm quality of the male and increases the sperm quantity
    The object of the invention is in each case independent of a combination preparation comprising at least one antioxidant as well as citrulline and / or omega-3 fatty acids or comprising at least one of the active ingredients C-vitamins, E-vitamins, zinc, selenium, acetylcysteine, L-camrtine, glutathione , Lycopene, ubiquinone Λί / m mrn H 1c.11 DCfil NZ011 / 15300 p nn7 / n 7 25 15:15:24 26-07-2011 8/27 • • • * * * * * · · »· · • * * · · ·············································································································· (-1) -4-1 Q component, wherein at least citrulline and / or omega-3 fatty acids Citrulline shows very good bioavailability, which allows the organism to produce the spermine spermine and spermidine, which are present in high concentration in the sperm fluid, as well as the protamines that are responsible for the packaging of spermatozoa - DNA is necessary and the DNA can stabilize, produce in sufficient quantities Omega-3 fatty acids have a positive effect on the fusion of egg and sperm cell, as well as the prostaglandin and steroid hormone metabolism.For many patients (about 70%) improves the routine Administration of additional antioxidants of the combined preparation the Spermienqu On the other hand, patients who do not benefit from such a measure do not have any negative side effects to worry about. C-vitamins of the combination drug interrupt the radical chain reaction and thus neutralize hydroxy, hyperoxide, and hydrogen dioxide radicals. C-vitamins act as the main antioxidant in the seminal plasma of fertile men, here the concentration is even ten times higher than in the blood plasma. In the seminal fluid of infertile men is usually found only a small amount. E-vitamins are localized in the cell membrane and very effectively interrupt the radical chain reaction, thereby neutralizing mainly H 2 O 2, OH and O 2 -. This protects the cell membrane from lipid oxidation. It is particularly advantageous that sperm motility is improved in 60% of patients with asthenozoospermia.
    Selenium of the combination preparation may improve sperm motility, viability and sperm morphology in OAT patients. In addition, the sperm DNA is protected from oxidative stress by promoting the protamine packaging of DNA and it also has antioxidant activity as a component of glutathione peroxidase. Selenium also works synergistically with vitamin E. N2011 / 15300 λ r »/ m / ^ η -» λ ί c. Λ "f Μ κ DEfll p nna / n 7 25 15:16:06 26-07-2011 9/27
    5
    Zinc is an essential component of spermatocytes. If the body does not have enough zinc for sperm production, it will decrease significantly. The motility of sperm cells also decreases because zinc contributes to the binding of the seed head to the seed tail. The additional zinc of the combination preparation leads to an improved spermiogram in infertile men. The combination of zinc with folic acid results in a 74% increase in sperm count. In addition, a treatment over a period of 3 months leads to a significant improvement in astenozoospermia. Zinc, which is involved in almost old biochemical processes in the body, supports the action of the combination preparation according to the invention. L-camitine in the combination preparation acts as a receptor molecule for activated fatty acids in the cytosol and in the mitochondria (in interplay with acetyl-CoA) and is an important energy substrate for the spermatozoa. However, camitins are also antioxidants that reduce the amount of reactive oxygen species by removing excess intracellular acetyl CoA. This will otherwise increase ROS production through the mitochondria. L-camitine also improves sperm motility. Camitin, more precisely L-camitine, plays an essential role in the energy metabolism of animal cells.
    The addition of glutathione to the combined preparation significantly increases sperm motility. In addition, glutathione reduces DNA damage by ROS. The tripeptide glutathione (cysteine, glutamate, glycine) is the most abundant antioxidant in the human body. It protects lipids, proteins and nucleic acids from oxidative stress. Glutathione is found in almost old cells in high concentration and is one of the most important antioxidant substances in the body. At the same time it is a reserve for cysteine. in combination with vitamin E and selenium, it forms glutathione peroxidase. However, administration of glutathione as a dietary supplement alone does not always lead to the desired success, as the oral administration only leads to a moderate increase in circulating glutathione in the body. However, by oral administration of N-acetylcysteine of the combination preparation, an important precursor molecule of glutathione, the glutathione content in cells can be effectively increased. Orally administered N2011M5300
    PM r ΛΛ / Λ7 / ΟΛ11 1C10 □ cm ηηο / η 7 25 15:16:50 26-07-2011 10/27 • «· · ·» «· * · **« «·« · «··« Over a period of 3 months leads to a significant increase in the overall antioxidant. * * * * * * ** ** * * * * ** ** Capacity in the plasma. This is associated with lower viscosity and thus with improved motility of the seed.
    Lycopene, also called lycopene or leucopin, is one of the antioxidants and is considered a scavenger, that is, it can kill certain reactive molecules in the human body. Lycopene is a carotenoid with very good antioxidant and anti-inflammatory properties. By means of these anti-inflammatory properties, it reduces the seminal production of ROS by leukocytes through the addition in the combined preparation.
    The addition of the ubiquinone-10 component (coenzyme Q10) in the combined preparation leads to an increase in the sperm quantity and to an improvement in mobility. Coenzyme Q10 (CoQ10) is required by the body for, among other things, energy production in the mitochondria. In sperm you will find it therefore especially in the middle piece. It also has antioxidant properties in that it recycles vitamin E and stops its pro-oxidative activity. The tissue concentration of coenzyme Q10 decreases with increasing Atter, which can be compensated by the combination preparation, this decrease. The administration of the combination preparation with oral CoQ-10 to infertile male subjects significantly increases the rate of fertilization. CoQ-10 also prevents the formation of H2O2 in seminal fluid.
    Folic acid supports the protamine packaging of sperm DNA. By a fbl-acid-poor diet of the man increases the number of sperm with chromosomal aberrations. Men who consume a large amount of folic acid via their diet or via vitamin supplements have significantly fewer sperm with a dis-order of the X chromosome (Klinefelter) or chromosome 21 (Down's syndrome) or a nullillogeny of the X chromosome (Turner). Taking into account other factors such as age, alcohol consumption and comorbidity, men with the highest folic acid intake (722-1150 pg / d) have 20-30% fewer sperm with aneupiiodia in the ejaculate than those with the lowest folic acid intake. Per 100 pg of folic acid, the risk decreases by 3.6 percent. Further, Fol- N2D11 / 15300 < ic (in 1 om 1 1S'1Q Mr Ri; ni P 010/027 15:17:32 26-07-2011 11/27 25 • «** ft» ··· * * * * * * * * Ft * tt # # * * * * * * * * ft ft * * «* * * ft * ft * ft * * ft ft · · · "Acid also homocysteine metabolism, which counteracts hyperhomocysteinemia and thus has an additional beneficial effect on spermiogenesis.
    The combination preparation improves the membrane structure of the spermatozoa through high-quality omega-3 fatty acids, which is particularly important for the fusion of the sperm cell and ovum during the actual fertilization, because a balanced membrane structure of the cells plays an important role in healthy sperm function. Non-fertile men have a lower proportion of polyunsaturated fatty acids compared to fertile men, especially a lower proportion of omega-3 fatty acids. This is accompanied by reduced sperm attraction, mobility and sperm structure. An intake of omega-3 fatty acids can counteract these problems. A positive side effect is the protective effect of omega-3 fatty acids on the prostate and cardiovascular system. The membrane is largely made up of fats. Altered nutritional conditions have been shown to alter the relative proportions of various fatty acids in cell membranes in recent years. In particular, the essential polyunsaturated omega-3 fatty acids are relatively insufficient in relative terms. This has an influence on processes such as the fusion of egg and sperm cell, as well as the prostaglandin and steroid hormone metabolism. While saturated and monounsaturated fats have been shown to be detrimental to sperm quality, both omega-6 and omega-3 fatty acids are very good for sperm quality. Also of importance is the ratio of omega-3 fatty acids to omega-6 fatty acids.
    The combination preparation may also contain citruliin. Citrulline is used by the body for the synthesis of arginine. An important feature of arginine is that it is in turn precursor of the neurotransmitter nitric oxide (NO). The enzyme nitric oxide synthase catalyzes the conversion of the amino acid arginine into the endothelium-derived relaxing factor (EDRF) - another name for nitric oxide. This diffuses into the muscle layers of the vessels or the corpus cavemosum. There he leads via the activation of the enzyme guanylate cyclase to an increased release of cyclic guanosine mono- N2011 / 15300
    Ofi I Π7 / ΟΓΜ 1 1 K on mp ρςηι P.011 / 027 25 15: 18; 17 26-07-20Π 12/27 -8- phosphate (cGMP). The increase of cGMP causes a relaxation of the smooth muscles and thus a lowering of the vascular tone. Thus, the gaseous NO triggers relaxation in the heart muscle and smooth vascular muscles.
    The amino acid L-arginine thus improves the release of nitric oxide, the circulation and oxygen supply to the coronary and peripheral blood vessels, inhibits clot formation in platelets and lowers blood pressure. This mechanism can also increase the erectile ability of the penis.
    Arginine is also necessary for normal spermatogenesis. From Argi-nin, the body forms spermine and spermidine, which are highly concentrated in the spermatic fluid, and the protamines necessary for the packaging of sperm DNA stabilize the DNA.
    The combination preparation leads in infertile men already after 6 to 8 weeks to an increase in sperm quantity and mobility Arginine, however, has the disadvantage of orally administered no optimal bioavailability. The amino acid L-citrulline is an important precursor for the production of arginine in the body but unlike arginine it is absorbed much better enterally. It therefore has a very good bioavailability. Ingested orally, L-citrulline is excreted into the bloodstream via the intestine and converted into L-arginine by the body. Studies have shown that supplementation with citrulline can raise arginine levels more effectively than if the same dose of arginine was taken directly. Because the body converts citrulline into arginine with a time delay, citrulline acts as a sustained-release agent according to the sustained-release function and increases the arginine level in the blood over a longer period of time. Thus, the organism benefits from a noticeably longer arginine effect. The use of citrulline to produce a combination preparation comprising at least antioxidants to improve sperm quality also proves beneficial. N2011 / 16300
    Dtn 1 pm / N 7 25 15:18:57 26-07-2011 13/27 • • mm * * Λ m · • «« »-9- Gürstig also shows a relationship of eicosapentaenoic acid to Docosahexae 3-to-2 acid because it can increase the sperm count and improve motility and sperm structure.
    By selecting the amounts of the active ingredients C vitamins in amounts of 1 to 20 wt .-%, in particular 5 to 15 wt .-%, preferably 6 to 10 wt .-%, E vitamins in amounts of 1 bic 20 Gow. %, in particular 5 to 10% by weight, preferably 6 to 10% by weight, of B9 vitamins in amounts of 0.005 to 2% by weight, in particular 0.009 to 1% by weight, preferably 0, From 0.1 to 0.1% by weight, zinc in amounts of from 0.5 to 5% by weight, in particular from 0.8 to 3.5% by weight, preferably from 1.2 to 2.5% by weight, Selenium in amounts of 0.001 to 1 wt .-%, in particular 0.004 to 0.5 wt .-%, preferably 0.006 to 0.1 wt .-%, acetylcysteine in amounts of 0.5 to 10 wt .-%, in particular 1 up to 6% by weight, preferably 2.5 to 4.5% by weight, camitin in amounts of 3 to 30% by weight, in particular 5 to 25% by weight, preferably 10 to 23% by weight, Glutathione in amounts of 0.5 to 15 wt .-%, in particular 1 to 10 wt .-%, preferably 3 to 6 wt .-%, lycopene in amounts of 0.05 to 3 wt .-%, in particular 0.08 to 1 wt .-%, preferably 0.2 to 0.1 wt .-%, and e Ubiquinone 10 component in amounts of 0.05 to 10 wt .-%, in particular 0.1 to 5 wt .-%, preferably 0.8 to 3 wt .-%, and omega-3 fatty acids in amounts of 5 to 50% by weight, in particular 10 to 40% by weight, preferably 20 to 35% by weight, and / or citrulline in amounts of 5 to 40% by weight, in particular 8 to 30% by weight, preferably 12 to 20 wt .-%, based on the total weight of the therapeutically active agents of the combination preparation, the above-described positive effects of the individual active ingredients in an optimal relationship to each other and thus the sperm quality and number increased most effectively.
    The addition of B6 vitamins and B12 vitamins in the combined preparation supports vascular function by lowering homocystic acid levels, thus supporting adequate sperm production and spermogenesis. N2011 / 1S300 M »η λ! rnm 1 1 c. 01 The 1 p rm / n 7 25 ♦ ·
    15:19:39 26-07-2011 14/27 -10-
    Copper is a component of many enzymes (metalloenzymes) and therefore a vital trace element and can therefore also support optimal sperm production.
    Due to the great antioxidant potential of the other carotenoids, sperm quality is also improved
    Advantageously, the addition of copper in amounts of 0.001 to 1 wt .-%, in particular 0.003 to 0.5 wt .-%, preferably 0.05 to 0.1 wt .-%, B6-vitamins in amounts of 0 proves , 05 to 3 wt .-%, in particular 0.08 to 1 wt .-%, preferably 0.2 to 0.1 wt .-%, B12 vitamins in amounts of 0.001 to 1 wt .-%, in particular 0.003 to 0.5% by weight, preferably 0.05 to 0.1% by weight, of further carotenoids, such as β-carotene, α-carotene, β-cryptoxanthin, lutein and zeaxanthin in amounts of 0.05 to 3% by weight. %, in particular 0.08 to 1 wt .-%, preferably 0.2 to 0.1 wt .-%, based on the total weight of the therapeutically active agents of the combination preparation, because characterized the previously described beneficial effects are cumulative on the development affect the sperm. By the described composition of the combination preparation, the interaction of the individual substances with each other are optimized and the synergy effects additionally enhanced. In addition, a balanced interaction with the other substances can be achieved.
    The combination preparation can be used both as a drug or balanced diet and as a dietary supplement, whereby the user is guaranteed in the approval as a drug or balanced diet that the drug has undergone at least a clinical trial and when approved as a dietary supplement a simple and optionally discrete access to the preparation is given
    Citrutlin also proves to be advantageous for the treatment of oligozoospermia, asthenozoospermia and / or teratozoospermia. Advantageously, citrulline proves to be administered in daily doses of 100 mg to 1000 mg, in particular 150 mg to 500 mg, preferably 200 mg to 300 mg, thus ensuring that an appropriate level of citrulline is present in the organism and N2011 / 15300 oo jm Mn · m 1 c. oo m. , The Ρ.Π14 / Π97
    2S 15:20:21 26-07-2011 2S 15/27
    Thus, a normal spermatogenesis can be done. This promotes a high sperm volume and good sperm motility.
    Citrulline is in amounts of 2 to 50 wt .-%, in particular 5 to 35 wt .-%, preferably 10 to 20 wt .-%, based on the total weight of the therapeutically active agents of the combination preparation, whereby on the one hand a sufficient effect of citrulline On the other hand, there is no danger of overdosage. Due to the selected proportion by weight, there is also good processability in the preparation of the combination preparation.
    The invention describes citrulline for use in a therapeutic method for the treatment of a restricted spermiogram. The combination with antioxidants is particularly advantageous. An antioxidant in the context of the invention is a chemical compound that specifically prevents unwanted oxidation of other substances. Antioxidants have great physiological significance due to their action as radical scavengers. They inactivate reactive oxygen species (ROS) in the organism, the abundance of which leads to oxidative stress. Oxidative stress is considered to be contributing to the process of attrition and impairment of fertility and is also associated with the development of a number of diseases.
    Furthermore, the invention describes citrulline for use in a method for the preparation of a combination preparation for the treatment of a restricted spermiogram. The effects of the various active ingredients of the combination preparation have already been described in advance. The combination preparation proves to be particularly advantageous for the treatment of a restricted spermiogram in oligozoospermia, asthenozoospermia and / or titeratozoospermia by the targeted selection of the active ingredients in the corresponding amounts. Particularly advantageous is a combination of C vitamins, E vitamins, zinc, selenium, acetylcysteine, L-camitine, glutathione, lyoopen, ubiquinone-10 component with citrulline and / or omega-3 fatty acids.
    Ms omega-3 fatty acids are preferably used eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). But it can also be α-Unolensäure (ALA) 26/07/2011 15:22
    No .: R501 P.015 / 027 25 15:21:04 26-07-2011 16/27 * *
    -12- be used as omega-3 fatty acid in the combination preparation. Preferably, fish oil is used for the preparation of the combination preparation, with 18% being DHA and 12% EPA. Omega-3 fatty acids of both animal and vegetable origin can be used.
    The combination preparation according to the invention is especially for the needs of the male organism when children want. It can be both a dietary supplement, a dietary supplement for special medical purposes (complementary balanced diet), as well as a medicinal product.
    Furthermore, the combination preparation according to the invention exhibits a specially adapted mixture of antioxidants, partly in depot form, and other nutrients and minerals important for the reproductive cells. For example, vitamin C is added as a sustained-release form. Preparations for a sustained release of active ingredients are described in the prior art. For example, vitamin O may be coated with hydroxypropyl methylcellulose. Thus, an optimal supply of the man is available. Of course, other known from the prior art methods for the delayed release of vitamin C can be applied.
    The mechanisms of action of the individual substances in the combination preparation according to the invention are complex. In addition to nutrient administration and enzyme induction, an essential mechanism of action is the targeted reduction of oxygen radicals.
    The Kumüii idUun of the coordinated active ingredients in the combination preparation according to the invention has been shown in studies that it comes in men to a significant improvement in their fertility
    The mechanisms described above work preferably in combination of the active ingredients and by supporting several antioxidants.
    Due to the synergistic effect of the individual active substances in the selected quantitative ranges, the effectiveness with respect to sperm quality and quantity of the combination preparation according to the invention can be achieved.
    N2011H63W Oss / ΙΊ7 / 9Π1 1 ß-'Nr · · Ol P Olfi / 027 25 15:21:45 26-07-2011 17/27 · · 4 4 4 4 4 4 4 4 4 4 4 4 4 • »·
    * · · - · »« · -13-
    The use of citrulline, optionally in combination with at least one antioxidant or omega-3 fatty acids with at least one antioxidant and the combination preparation according to the invention is preferably recommended for oral administration. The preparation can be used both as a human and veterinary product.
    The following table shows the quantitative ranges of the recommended daily dose of the individual active substances relevant for the invention. Preferably, the combination preparation according to the invention is taken as two capsules per day. However, the drug levels can be chosen so that only one capsule per day is required to reach the recommended dosage.
    Active ingredient Recommended amount range in mg per day Vitamin C 50-200 Vitamin E 10-120 Folic acid 0.1-0.7 Zinc 5-50 Selenium 0.02-0.2 Acetylcysteine 10-100 Camitin 10-500 Glutathione 10-100 Lycopene 1-15 Ubiquinone-10 Component 1-50 Omega-3 100-1000
    OR / fl7 / C> ni1 IR'W
    Nr · R *; ni N2011 / 15300 p ni7 / n 7 -14- 15:22:14 26-07-2011 18/27 25
    Fatty Acids Citrulline 1-600 Copper 0.05-10 Vitamin B12 0.01 -1 Vitamin ΒΘ 1-10 Carotenoids 0 1 O
    There are also excipients, such as HiKsstoffe, fillers, carriers, Bindemittei, etc., which are required for the technical processability of the combination preparation according to the invention, included. However, these excipients have no therapeutic efficacy and no positive effects on the sperm and are therefore not therapeutically active agents within the meaning of the invention.
    In the following, exemplary embodiments of the composition of the therapeutically active substances in mg per daily dose of the combination preparation according to the invention are mentioned, which achieves the advantageous effects.
    Active ingredient 1 2 3 4 6 6 7 8 9 10 Vitamin C 50 120 150 100 180 200 100 80 100 Vitamin E "10 20 50 100 100 120 100 60 80 Folic acid 0.1 0.3 0.3 0.5 0.6 0.7 0.5 0.4 0.5 zinc "5 10 15 25 40 50 25 30 10 selenium • 0.02 0.05 0.07 0.1 0.1 0.2 0.1 0.09 0 , 15 acetylcysteine 10 40 30 50 90 100 50 80 80 Ν2011Π5300 i) ein7ionu 1 κ O / i no QRm P.01R / 027 -15- 25 15:22:47 26-07-2011 19/27 «*
    Carnitine - 10 100 200 300 400 500 300 250 350 Glutathione - 10 20 25 50 80 100 50 90 70 Lycopene 1 2 3 4 2,5 15 4 13 10 Ubiquinone-10 Component 1 3 10 15 15 50 15 30 40 Omega-3 - Fatty Acids 100 200 400 500 350 1000 500 700 900 Citrulline 500 100 300 800 300 600 600 200 60 10 Copper "'0.5" 1 "• Vitamin B12" 0.05 "• 0.01" 0.09 Vitamin B6 mm 1 • 3 2 carotenoids ~ " 5 • 5 "3 ** 3 Fillers and carriers ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
    In experiments it could be demonstrated that the Ausfqhrungsbeispiel 5 shows particularly good activity. So it comes with a composition according to Embodiment 5 to an improvement of the spermiogram and to about 20% increased fertilization rate. In general, it has been demonstrated that with the preparation according to the invention the sperm quantity and quality is significantly improved in over 70% of men.
    In the table below, the compositions of the active compounds in absolute numbers of two combination preparations according to the invention which exhibit the advantageous effects are described by way of example. N2011 / 16300 oe / m / omi ik oc
    Mr π around P 019 / ΠΡ7 25 15:23:22 26-07-2011 20/27
    • · • · -16-
    Active ingredient Amount In mg per daily dose% by weight Amount in mg per daily dose% by weight Vitamin C 100 7.43715603 100 7.38814602 Vitamin E 100 7.43715603 100 7.38814602 Folic acid (vitamin B9) 0.5 0.03718578 0.5 0.03699073 zinc 25 1.85928901 25 1.84953651 selenium 0.1 0.00743716 0.1 0.00739815 acetylcysteine 50 3.71857802 50 3.69907301 camitin 300 22.3114681 300 22.1944381 glutathione 50 3, 71857802 50 3,699,007301 Lycopene 4 0,29748624 4 0,29592584 Ubiquinone-10 Component 15 1,1155734 15 1,1097219 Omega-3 fatty acids 500 37,1857802 500 36,9907301 Citrulline 300 14,8743121 300 14,796292 Copper * 0 3 0.22194438 Vitamin B12 0 0.09 0.00665833 Vitamin B6 0 1 0.07398146 Carotenoids 0 3 0.22194438 In a preferred embodiment, the combination preparation according to the invention consists of L-camitin, L-ascorbic acid, D-alpha tocopheryl acetate, Folic Acid, Silica, Calcium Carbonate, N-Acetyl-L Cysteine, Glutathione, Corn Starch- 26/07/2011 15:25
    No .: R501 P.020 / 027 25 15:23:54 26-07-2011 21/27
    • * Μ -17-ke, zinc oxide, coenzyme Q10, lycopene, vegetable oils, pteroyl-L-glutamate, sodium umselenite, fish oil and citrulline. The capsule shell is preferably cellulose, but may be of another type. The vegetable oils come from the fact that the raw material lycopene is liposoluble and is offered dissolved in them. Instead of sodium selenite, the organic variant of L-selenomethionine can also be used. The corn starch is a carrier of otherwise oily vitamin E.
    The beneficial effect of citrulline and the combination preparation according to the invention can be utilized in preparation for natural pregnancy as well as in preparation for insemination, in vitro fertilization as well as intracytoplasmic sperm injection.
    The combination preparation according to the invention should be taken orally twice a day in the form of a capsule. The recommended minimum income is 3 months. All statements on ranges of values in the description of the present invention should be understood to include any and all sub-ranges thereof, e.g. the indication 1 to 10 should be understood to include all sub-ranges, starting from the lower limit 1 and the upper limit 10, i. all sub-regions begin with-a lower limit of 1 or greater and end at an upper limit of 10 or less, e.g. 1 to 1.7, or 3.2 to 8.1 or 5.5 to 10.
    The embodiments show possible embodiments of the combination preparation, it being noted at this point that the invention is not limited to the specifically illustrated embodiments thereof, but also various combinations of the individual embodiments are possible with each other and this possibility of variation due to the teaching of technical action by representational Invention in the skill of those skilled in this technical field. So are all possible design variants, which are possible by combinations of individual details of the embodiment described, includes the scope of protection. N2011 / 15300 ftp ιήΙ / ΊΛ 11 IfL-Ofi M r · ocm P Π91 IO 7
    The problem underlying the independent inventive solutions can be taken from the description. N2011 / 15300
    权利要求:
    Claims (10)
    [1]
    25 15:24:55 26-07-2011 23/27 # ····································································································································································································· 1. A combination preparation for improving sperm quantity and quality comprising at least one antioxidant, characterized in that it contains ci-trulline and / or omega-3 fatty acids. ______________________________________ are.
    [2]
    2. Combination preparation according to claim 1, characterized in that at least one of the active ingredients C vitamins, ΕΛ / itamine, zinc, selenium, acetylcysteine, L-carnitine, glutathione, lycopene, Ubiquinon-10 component is included.
    [3]
    3. Combination preparation according to claim 1 or 2, characterized in that the omega-3 fatty acids eicosapentaenoic acid to Docosahexaensäure in a ratio of 3 to 2 is included.
    [4]
    4. Combination preparation according to one of claims 1 to 3, characterized in that C-vitamins in amounts of 1 to 20 wt .-%, in particular 5 to 15 wt .-%, preferably 6 to 10 wt .-%, E-vitamins in amounts of 1 to 20 wt .-%, in particular 5 to 15 wt .-%, preferably 6 to 10 wt .-%, 59 vitamins in amounts of 0.005 to 2 wt .-%, in particular 0.009 to 1 wt. %, preferably 0.01 to 0.1 wt .-%, zinc in amounts of 0.5 to 5 wt .-%, in particular 0.8 to 3.5 wt .-%, preferably 1.2 to 2.5 Wt .-%, selenium in amounts of 0.001 to 1 wt .-%, in particular 0.004 to 0.5 wt .-%, preferably 0.006 to 0.1 wt .-%, acetylcysteine in amounts of 0.5 to 10 wt. -%, in particular 1 to 6 wt .-%, preferably 2.5 to 4.5 wt .-%, camitin in amounts of 3 to 30 wt .-%, in particular 5 to 25 wt .-%, preferably 10 to 23 % By weight of glutathione in amounts of from 0.5 to 15% by weight, in particular from 1 to 10% by weight, preferably from 3 to 6% by weight, of lycopene in amounts of from 0.05 to 3% by weight , in particular 0.08 to 1 wt. -%, preferably 0.2 to 0.1 wt .-%, and a Ubiquinon-10 component in amounts of 0.05 to 10 wt .-%, in particular 0.1 to 5 wt .-%, N2011 / 15300 OR / Π7 / 9Π1 1 1 IR · 97 Mr · Β * / 11 P / 199 // 197 25 1S: 25: 32 26-07-2011 24/27 • ft * · ·· * · * «* ♦ · * * * * * * * * * * * * * «* * 4» * *, * * * · · · »I · v * · 4 4 ft · ft * -2 preferably 0, 8 to 3 wt .-%, and omega-3 fatty acids in amounts of 5 to 50 wt .-%, in particular 10 to 40 wt .-%, preferably 20 to 35 wt .-%, and / or citruliin in amounts of 0.5 to 40 wt .-%, in particular 1 to 30 wt .-%, preferably 12 to 20 wt .-%, based on the total weight of the therapeutically active agents of the combination preparation enthaften.
    [5]
    5. Combination preparation according to one of claims 1 to 4, characterized in that copper, other carotenoids, B6-Vrtamine, B12 vitamins are included.
    [6]
    6. Combination preparation according to claim 5, characterized in that copper in amounts of 0.001 to 1 wt .-%, in particular 0.003 to 0.5 wt .-%, preferably 0.05 to 0.1 wt .-%, Bo-vitamins in amounts of from 0.05 to 3% by weight, in particular from 0.08 to 1% by weight, preferably from 0.2 to 0.1% by weight, of B12 vitamins in amounts of from 0.001 to 1% by weight , in particular 0.003 to 0.5 wt .-%, preferably 0.05 to 0.1 wt .-%, extended carotenoids, such as ß-carotene, a-carotene, ß-cryptoxanthin, lutein and zeaxanthin in amounts of 0.05 to 5 wt .-%, in particular 0.08 to 1 wt .-%, preferably 0.2 to 0.1 wt .-%, based on the total weight of the therapeutically active agents of the combination preparation are included.
    [7]
    7. Use of the combination preparation according to one of claims 1 to 6 as a medicament, balanced diet and / or dietary supplements.
    [8]
    8. Citruliin for the treatment of oligozoospermia, asthenozoospermia and / or teratozoospermia.
    [9]
    9. Citruliin according to claim 8, characterized in that it is contained in a combination preparation comprising therapeutically active agents, such as at least one antioxidant N2011 / 15300 nc ΙΠ7 / ΟΛ11 14 ΟΊ iir Qf ^ m P Γ ΟΑΙΓ 07 15:26: 06 26-07-2011 25/27 25 m • • * Mt * | ft * ft * »* * ft ft 9 Λ V * * C 4 ft ft · ft ft« > ft 'ft ft • * ft • *% • ft • • • ♦ * ft' ft ft -β ίο. Citrulline according to claim 8 or 9, characterized in that it is administered in daily doses of 1 mg to 600 mg, in particular 10 mg to 500 mg, preferably 200 mg to 400 mg.
    [10]
    11. citrulline according to claim 8 to 10, characterized in that it is in amounts of 0.5 to 40 wt .-%, in particular 5 to 35 wt .-%, preferably 10 to 20 wt based on the total weight of the therapeutically active agents of the combination preparation is included. Gonadosan GmbH by Attorneys ^ & y ^ Partner Attorney GmbH N2011 / 15300 Kl - π nir ni nr λ H 1 C · io DK Λ 1 p ftptwn 7 (new) Claims 1. Combination preparation comprising at least one antioxidant and Ci-trullin for use in the treatment of sperm quantity and quality improvement. 2. Combination preparation according to claim 1, characterized in that at least one active ingredient selected from a group comprising C-vitamin, E-vitamins, zinc, selenium, acetylcysteine, L-carnitine, glutathione, lycopene, Ubiquinon-10 component, omega-3 Contains fatty acids. 3. Combination preparation according to claim 2, characterized in that the omega-3 fatty acids eicosapentaenoic acid to Docosahexaensäure in a ratio of 3 to 2 is included. 4. Combination preparation according to one of claims 1 to 3, characterized in that C-vitamin in amounts of 1 to 20 wt .-%, in particular 5 to 15 wt .-%, preferably 6 to 10 wt .-%, E-vitamins in amounts of 1 to 20 wt .-%, in particular 5 to 15 wt .-%, preferably 6 to 10 wt .-%, B9 vitamins in amounts of 0.005 to 2 wt .-%, in particular 0.009 to 1 wt. %, preferably 0.01 to 0.1 wt .-%, zinc in amounts of 0.5 to 5 wt .-%, in particular 0.8 to 3.5 wt .-%, preferably 1.2 to 2.5 Wt .-%, selenium in amounts of 0.001 to 1 wt .-%, in particular 0.004 to 0.5 wt .-%, preferably 0.006 to 0.1 wt .-%, acetylcysteine in amounts of 0.5 to 10 wt. -%, in particular 1 to 6 wt .-%, preferably 2.5 to 4.5 wt .-%, carnitine in amounts of 3 to 30 wt .-%, in particular 5 to 25 wt .-%, preferably 10 to 23 % By weight of glutathione in amounts of from 0.5 to 15% by weight, in particular from 1 to 10% by weight, preferably from 3 to 6% by weight, of lycopene in amounts of from 0.05 to 3% by weight , in particular 0.08 to 1 wt. %, preferably 0.2 to 0.1% by weight, and a ubiquinone 10 component in amounts of 0.05 to 10% by weight, in particular 0.1 to 5% by weight, preferably 0, From 8 to 3% by weight, and omega-3 fatty acids in amounts of from 5 to 50% by weight, in particular from 10 to 40% by weight, preferably from 20 to 35% by weight, and / or citmentin in quantities from 0.5 to 40 wt .-%, in particular 1 to 30 wt%, preferably 12 to 20 wt .-%, based on the total weight of the therapeutically active agents of the combination preparation are included. 5. Combination preparation according to one of claims 1 to 4, characterized in that copper, other carotenoids, B6 vitamins, B12 vitamins are included. 6. Combination preparation according to claim 5, characterized in that copper in amounts of 0.001 to 1 wt .-%, in particular 0.003 to 0.5 wt .-%, preferably 0.05 to 0.1 wt .-%, B6 vitamins in amounts of from 0.05 to 3% by weight, in particular from 0.08 to 1% by weight, preferably from 0.2 to 0.1% by weight, of B12 vitamins in amounts of from 0.001 to 1% by weight , in particular 0.003 to 0.5% by weight, preferably 0.05 to 0.1% by weight, of further carotenoids, such as β-carotene, α-carotene, β-cryptoxanthin, lutein and zeaxanthin in amounts of 0.05 to 5 wt .-%, in particular 0.08 to 1 wt .-%, preferably 0.2 to 0.1 wt .-%, based on the total weight of the therapeutically active agents of the combination preparation are included. 7. Combination preparation according to one of claims 1 to 6, characterized in that citruliin in daily doses of 1 mg to 600 mg, in particular 10 mg to 500 mg, preferably 200 mg to 400 mg is administered. 8. Use of the combination preparation according to one of claims 1 to 7 as a medicament, balanced diet and / or dietary supplements. Gonadosan GmbH through

    Attorney artner Right H FOLLOW-UP A2011 / 01093
    类似技术:
    公开号 | 公开日 | 专利标题
    US7887847B2|2011-02-15|Nutritional supplement for treatment of ocular diseases
    DE60201824T2|2005-03-31|FOOD SUPPLEMENT FOR THE TREATMENT OF MACULAR AGENCY
    AT503219B1|2008-07-15|COMBINATION PREPARATION BASED ON ANTIOXIDANTS TO IMPROVE THE SEED QUALITY
    US20070292493A1|2007-12-20|Pharmaceutical composition and method for the transdermal delivery of calcium
    JP5084512B2|2012-11-28|Antioxidant dietary supplement compositions and methods for maintaining healthy skin
    EP0755633B1|1999-10-27|Two phases preparation
    DE202011050351U1|2011-11-24|Dietetic products or formulations
    EP1637149A1|2006-03-22|Dietary supplement composition for the man
    EP2648807B1|2018-01-24|Combination preparation for improving female fertility
    EP2736354B1|2017-08-16|Use of citrulline and combination compound for improving male fertility
    EP2929879B1|2020-03-18|Combination preparation for treating infertility which is associated to endometriosis
    DE102007053369A1|2009-07-02|Use of a preparation containing a creatine-component and a further component of e.g. L-carnitine, acetyl-L-carnitine, arginine, glutathione, vitamin C and vitamin E, as a dietary supplement for improving the male fertility in vertebrates
    DE102011008478A1|2011-08-04|Integral dietary supplement with a physiological efficiency, useful for preventing e.g. prostate disorders, malnutrition, osteoporosis, cardiovascular disease, cancer, comprises dried broccoli, dried vegetables and/or dried fruits
    KR100270622B1|2000-11-01|A nutrition composition
    Black2015|The role of nutritional lipids and antioxidants in UV-induced skin cancer
    AT510761A1|2012-06-15|USE OF A UBIQUINONE COMPONENT AND A COMBINATION PREPARATION TO IMPROVE FEMALE FERTILITY
    AT513274B1|2014-03-15|Dietary supplements
    EP1437051A1|2004-07-14|Ocuvite lutein
    EP2508082B1|2013-12-18|Food supplement preparation with amino acids and spice extract
    US11077085B2|2021-08-03|Dietary macro/micronutritional supplement for patients undergoing kidney dialysis
    DE202013002498U1|2013-03-22|Feed additive for pets and pets
    Singh et al.2014|19 Vitamins and Minerals: Roles and Plant Sources
    EP3111930A2|2017-01-04|Composition for treating depression, bipolar disorders, recurrent medical depressive disorders and other long-term affective disorders
    AT9808U1|2008-04-15|VITAMIN AND MINERAL MATERIAL PREPARATION AND ITS USE FOR IMPROVING THE SEED QUALITY
    Siemelink et al.2000|Active components in food supplements
    同族专利:
    公开号 | 公开日
    EP2736354B1|2017-08-16|
    EP2736354A1|2014-06-04|
    WO2013013979A1|2013-01-31|
    AT511776B1|2014-03-15|
    ZA201401469B|2015-10-28|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    US6028107A|1997-02-27|2000-02-22|Waugh; William Howard|Orthomolecular medical use of L-citrulline for vasoprotection, relaxative smooth muscle tone and cell protection|
    DE19812652A1|1997-10-30|1999-05-06|William H Waugh|Use of L-citrulline|
    EP1330957A2|2002-01-15|2003-07-30|Karl-Heinz Bauer|Nutritional supplement|
    EP1752156A1|2004-04-30|2007-02-14|National University Corporation Nara Institute of Science and Technology|Active oxygen eliminator and moisturizer containing wild watermelon extract|
    WO2006002096A2|2004-06-18|2006-01-05|Vivo Therapeutics, Inc.|Low doses of l-citrulline for treating diseases|
    WO2007087667A2|2006-02-03|2007-08-09|Fapa Vital Anstalt|Combination preparation for improving sperm quality|
    US20100233304A1|2008-01-04|2010-09-16|Yuanlong Pan|Compositions comprising unsaturated fatty acids and nitric oxide releasing compounds and use thereof for enhancing cognitive and related functions|
    US5874471A|1997-02-27|1999-02-23|Waugh; William Howard|Orthomolecular medical use of L-citrulline for vasoprotection, relaxative smooth muscle tone and cell protection|
    AU2003288606A1|2002-12-20|2004-07-14|Pronova Biocare As|Use of a fatty acid composition for treatment of male infertility|
    DE102008056312A1|2008-11-07|2010-05-12|Biogenerics Pharma Gmbh|Use of micro-tablets as food and feed additive|WO2019110097A1|2017-12-06|2019-06-13|Laboratoire Des Granions|Composition comprising l-carnitine for the treatment of male infertility|
    WO2019239268A1|2018-06-15|2019-12-19|Angelo Chieregati|Composition for the treatment of infertility|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    ATA1093/2011A|AT511776B1|2011-07-26|2011-07-26|USE OF CITRULLINE AND A COMBINATION PREPARATION FOR IMPROVING MALE FERTILITY|ATA1093/2011A| AT511776B1|2011-07-26|2011-07-26|USE OF CITRULLINE AND A COMBINATION PREPARATION FOR IMPROVING MALE FERTILITY|
    PCT/EP2012/063570| WO2013013979A1|2011-07-26|2012-07-11|Use of citrulline and combination compound for improving male fertility|
    EP12737759.6A| EP2736354B1|2011-07-26|2012-07-11|Use of citrulline and combination compound for improving male fertility|
    ZA2014/01469A| ZA201401469B|2011-07-26|2014-02-26|Use of citrulline and combination compound for improving male fertility|
    [返回顶部]